Johns Hopkins tech transfer is at the heart of a new agreement meant to bolster the development of a DNA-based vaccine for allergies.
Formally, Rockville-based Immunomic Therapeutics inked a licensing deal with Astellas Pharma, which will develop the allergy vaccine. Through the deal, Immunomic will receive an upfront payment of $300 million, and is entitled to 10 percent royalties from vaccine products developed. Astellas, a Japan-based pharmaceutical giant, gets the right to produce the vaccine worldwide.